Stay updated on Combination Dato-DXd Clinical Trial
Sign up to get notified when there's something new on the Combination Dato-DXd Clinical Trial page.

Latest updates to the Combination Dato-DXd Clinical Trial page
- Check7 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now renders a 403 Forbidden error with a minimal layout and a Home button. This replaces the previous study record content and indicates the study page is currently inaccessible due to access restrictions.SummaryDifference17%

- Check49 days agoChange DetectedA new release-note entry for 2023 (U.S. NIH Grant/Contract) was added. The revision tag was updated from v3.6.5 to v3.6.6.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded on 2026-08-19: expanded study description and expanded the set of outcomes with longer follow-up windows for PFS and OS in the Dato-DXd plus pembrolizumab arm. Deleted on 2026-06-12: non-squamous-only language and several earlier time-to-event definitions were replaced, aligning the text with the updated protocol.SummaryDifference1%

- Check70 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a new release of the site’s study page. This update likely applies backend or UI improvements rather than changes to the study data.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page's revision label was updated from Revision: v3.6.3 to Revision: v3.6.4, indicating a minor update to the page metadata.SummaryDifference0.0%

Stay in the know with updates to Combination Dato-DXd Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combination Dato-DXd Clinical Trial page.